OCT 13, 2020 8:00 AM PDT

Test for Diabetes Checks If the Liver Is Responding

WRITTEN BY: Tara Fernandez

Glucagon is a hormone that prevents blood glucose levels from dropping too low by stimulating the liver to convert stored glycogen into glucose. This is a critical physiological feedback loop between the liver and the pancreas, where glucagon acts as a messenger. It’s a delicate balance — too much glucagon and sugar production in the liver spikes, resulting in potentially harmful elevated blood sugar levels, a precursor to diabetes.

Researchers at the University of Copenhagen have discovered a new biomarker that provides a warning signal of an increased risk of type 2 diabetes. This new test measures glucagon resistance, or the inability of the liver to respond to signals from the glucose-balancing hormone. According to the scientists, measuring glucagon sensitivity could potentially predict the future onset of type 2 diabetes earlier than current diagnostic tests.

“Glucagon resistance is an entirely new biological concept that we will include in the future teaching of medical students, just as we do today with insulin resistance,” said Nicolai J. Wewer Albrechtsen, senior author in the study, published in Molecular Metabolism.

These findings could explain the phenomena wherein the majority of patients with type 2 diabetes also suffer from fatty liver disease. Though this condition (where abnormal levels of fat accumulate in the liver) is largely asymptomatic, it is closely linked to the regulation of the metabolism. The fatty liver has a reduced sensitivity to glucagon and subsequently, the pancreas responds by secreting even higher amounts of the hormone. If treated earlier, this could restore metabolic balance and prevent permanent damage of the pancreas.

“Our study points to a new biomarker (the glucagon-alanine index) that may be useful in identifying persons with impaired glucagon sensitivity. If we can detect glucagon resistance from a blood test, we can start treatment early and thus prevent the development of type 2 diabetes,” said Marie Winther-Sørensen, another author of the study.

Sources: Molecular Metabolism, University of Copenhagen.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
NOV 05, 2020
Clinical & Molecular DX
Digging DEEP into Metabolomic Space
NOV 05, 2020
Digging DEEP into Metabolomic Space
Metabolomics is an umbrella term encompassing lipidomics and the study of smaller polar metabolites.  As such, more ...
NOV 25, 2020
Cancer
Using RNA to Diagnose HPV Associated Cancer
NOV 25, 2020
Using RNA to Diagnose HPV Associated Cancer
Diagnostic tools are critical to modern medicine. They might be less exciting than a good therapy or drug, but doctors a ...
JAN 08, 2021
Neuroscience
Can We Identify Alzheimer's from Routine Eye Exams?
JAN 08, 2021
Can We Identify Alzheimer's from Routine Eye Exams?
As people with diabetes age, they are more likely than those without the condition to develop cognitive disorders such a ...
JAN 14, 2021
Clinical & Molecular DX
Tip of the Iceberg: Inaccuracies in Prostate Cancer Diagnostics
JAN 14, 2021
Tip of the Iceberg: Inaccuracies in Prostate Cancer Diagnostics
  Only 10 percent of icebergs are visible on the surface of the water; the remaining 90 percent remains submerged. ...
JAN 26, 2021
Clinical & Molecular DX
Prostate Cancer Screening: No More False Positives
JAN 26, 2021
Prostate Cancer Screening: No More False Positives
A new diagnostic test powered by artificial intelligence has been found to detect prostate cancer markers in urine sampl ...
JAN 26, 2021
Genetics & Genomics
Why Only Some People With a Rare Mutation Get a Heart Condition
JAN 26, 2021
Why Only Some People With a Rare Mutation Get a Heart Condition
Scientists have found a way to explain why a heart condition called hypertrophic cardiomyopathy (HCM) can be so differen ...
Loading Comments...